These finding suggest that GM-CSF can abrogate important aspects of the immune suppression seen in patients with advanced colorectal cancer and may provide a non-toxic intervention to augment anti-tumor immunity for cancer patients receiving cytotoxic chemotherapy. The gene discussed is CSF2; the disease is colorectal cancer.